PROJ-SUN_1170x120_6-24-20

Joerg Reinhardt

Novartis seeks approval to spinoff Alcon eye care biz

Novartis seeks approval to spinoff Alcon eye care biz

BASEL — Novartis today announced its intention to spinoff Alcon, its eye care division, into a separately-traded standalone company. The planned spinoff would enable Novartis and Alcon to focus fully on their respective growth strategies. Completion of the transaction is subject to general market conditions, tax rulings and opinions, final Board of Directors endorsement and shareholder

Novartis CEO Joseph Jimenez to step down

Novartis CEO Joseph Jimenez to step down

BASEL, Switzerland — Novartis chief executive officer Joseph Jimenez plans to retire from the company next year, to be succeeded by drug development chief Vasant Narasimhan. Plans call for Jimenez to step down on Jan. 31, 2018, and for Narasimhan, who is global head of drug development and chief medical officer at Novartis, to take